---
title: "Cyclacel (now Bio Green Med Solution) delays 2024 annual report"
url: "https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "NASDAQ:BGMS"
source: "https://www.sec.gov/Archives/edgar/data/1130166/000182912625002205/cyclacel_nt10k.htm"
summary: "Cyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days."
---

By the aibio.space news desk.

Sources

- [Bio Green Med Solution, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1130166/000182912625002205/cyclacel_nt10k.htm)

[BGMS](https://aibio.space/companies/bio-green-med-solution/)

2025-03-31

# Cyclacel (now Bio Green Med Solution) delays 2024 annual report

Tickers [BGMS](https://aibio.space/companies/bio-green-med-solution/)

Cyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days.

## Key facts

- **Company**: Bio Green Med Solution, Inc. (NASDAQ: BGMS)

- **News type**: Distress

- **Primary source**: [Bio Green Med Solution, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1130166/000182912625002205/cyclacel_nt10k.htm)

*The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Cyclacel Pharmaceuticals, Inc. (now Bio Green Med Solution, Inc.) told the Securities and Exchange Commission on March 31, 2025 that it could not file its annual report on Form 10-K for the fiscal year ended December 31, 2024 by the due date.

A Form 12b-25, often called an NT filing, tells the SEC that a periodic report will be late. Filing it on time gives a company a short grace period under Rule 12b-25(b). For an annual report, the grace period is fifteen calendar days after the original due date.

Cyclacel said it requires additional time "to gather necessary information for the preparation of such Form 10-K." It said it could not file on time without unreasonable effort or expense. The company said it expects to file the report within fifteen calendar days of the due date.

It said it has filed all other required periodic reports during the preceding 12 months, and it does not expect a significant change in results of operations from the prior year, according to the [notice](https://www.sec.gov/Archives/edgar/data/1130166/000182912625002205/cyclacel_nt10k.htm).

The notice lists the company's principal executive office in Kuala Lumpur, Malaysia.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

BGMS

Bio Green Med Solution, Inc.

NASDAQ · Malaysia

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cyclacel (now Bio Green Med Solution) delays 2024 annual report", 2025-03-31, https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/